Therapies for neovascular age-related macular degeneration: Current approaches and pharmacologic agents in development

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Hanout, Mostafa ^a,b   Ferraz, Daniel ^a,c   Ansari, Mehreen ^a   Maqsood, Natasha ^a   Kherani, Saleema ^a   Sepah, Yasir J ^a,b   Rajagopalan, Nithya ^b   Ibrahim, Mohamed ^a,b   Do, Diana V ^b   Nguyen, Quan Dong ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTIBODY; BEVACIZUMAB; EVIZON; KH 902; MP 0112; PAZOPANIB; PEGAPTANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RECOMBINANT PROTEIN; SIRNA 027; SONEPCIZUMAB; SPHINGOSINE 1 PHOSPHATE ANTIBODY; SQUALAMINE; UNCLASSIFIED DRUG; VATALANIB; VERTEPORFIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANTERIOR EYE CHAMBER DISEASE; BRACHYTHERAPY; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EPIRETINAL MACULAR BRACHYTHERAPY; EYE PAIN; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRITIS; LASER COAGULATION; NONHUMAN; PHOTODYNAMIC THERAPY; PUNCTATE KERATITIS; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; REVIEW; SIDE EFFECT; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITRITIS; ANIMAL; DRUG ANTAGONISM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MACULAR DEGENERATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890041542     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/830837     Document Type: Review

References (64)

1. Joussen A. M., Bornfeld N., The treatment of wet age-related macular degeneration. Deutsches Arzteblatt 2009 106 18 312 317 2-s2.0-69049102036 10.3238/arztebl.2009.0312
2. Gragoudas E. S., Adamis A. P., Cunningham E. T. Jr., Feinsod M., Guyer D. R., Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine 2004 351 27 2805 2816 2-s2.0-11144239923 10.1056/NEJMoa042760 (Pubitemid 40051904)
3. Hawkins B. S., Blackhurst D. W., Schachat A. P., Olk R. J., Novak M. A., Maguire M. G., Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Archives of Ophthalmology 1991 109 8 1109 1114 2-s2.0-0026409933
4. Hawkins B. S., Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 1991 109 9 1232 1241 2-s2.0-0025887896
5. Maguire M. G., Sternberg P., Brown J. M., Bressler N. M., Bressler S. B., Elman M. J., Haller J. A., Murphy R. P., Schachat A. P., Orr P. R., Macmillan K., Starr J., Singerman L. J., Rice T. A., Noval M., Smith-Brewer S., Preseren D., Fish G. E., Jost B., Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Archives of Ophthalmology 1994 112 4 489 499 2-s2.0-0028349664 (Pubitemid 24114071)
6. Virgili G., Bini A., Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007 3 CD004763 2-s2.0-35348889529
7. Roundtable V., Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) study group principal investigators; Verteporfin In Photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002 22 1 6 18
8. Kaiser P. K., Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Current Medical Research and Opinion 2009 25 8 1853 1860 2-s2.0-67651040051 10.1185/03007990903038616
9. Gragoudas E. S., Adamis A. P., Cunningham E. T. Jr., Feinsod M., Guyer D. R., Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine 2004 351 27 2805 2816 2-s2.0-11144239923 10.1056/NEJMoa042760 (Pubitemid 40051904)
10. Ruckman J., Green L. S., Beeson J., Waugh S., Gillette W. L., Henninger D. D., Claesson-Welsh L., Janjić N., 2'-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. Journal of Biological Chemistry 1998 273 32 20556 20567 2-s2.0-0032493654 10.1074/jbc.273.32.20556 (Pubitemid 28377626)
11. Brown D. M., Michels M., Kaiser P. K., Heier J. S., Sy J. P., Ianchulev T., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009 116 1 57 2-s2.0-57949094834 10.1016/j.ophtha.2008.10.018
12. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
13. Boyer D. S., Heier J. S., Brown D. M., Francom S. F., Ianchulev T., Rubio R. G., A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 116 9 1731 1739 2-s2.0-69249222585 10.1016/j.ophtha.2009.05.024
14. Rosenfeld P. J., Intravitreal avastin: the low cost alternative to lucentis? American Journal of Ophthalmology 2006 142 1 141 143 2-s2.0-33745386921 10.1016/j.ajo.2006.03.036 (Pubitemid 43946805)
15. Steinbrook R., The price of sight-Ranibizumab, bevacizumab, and the treatment of macular degeneration. The New England Journal of Medicine 2006 355 14 1409 1412 2-s2.0-33749426139 10.1056/NEJMp068185 (Pubitemid 44511554)
16. Tufail A., Patel P. J., Egan C., Hykin P., da Cruz L., Gregor Z., Dowler J., Majid M. A., Bailey C., Mohamed Q., Johnston R., Bunce C., Xing W., ABC Trial Investigators A. T. I., Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010 340 c2459 2-s2.0-77954470039 10.1136/bmj.c2459
17. Martin D. F., Maguire M. G., Ying G.-S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011 364 20 1897 1908 2-s2.0-79956218863 10.1056/NEJMoa1102673
18. Martin D. F., Maguire M. G., Fine S. L., Ying G. S., Jaffe G. J., Grunwald J. E., Toth C., Redford M., Ferris F. L. III, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012 119 7 1388 1398 10.1016/j.ophtha.2012.03. 053
19. Chakravarthy U., Harding S. P., Rogers C. A., Downes S. M., Lotery A. J., Wordsworth S., Reeves B. C., Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012 119 7 1399 1411
20. Heier J. S., Boyer D., Nguyen Q. D., Marcus D., Roth D. B., Yancopoulos G., Stahl N., Ingerman A., Vitti R., Berliner A. J., Yang K., Brown D. M., The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011 118 6 1098 1106
21. Holash J., Davis S., Papadopoulos N., Croll S. D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J. P., Daly T., Wiegand S. J., Yancopoulos G. D., Rudge J. S., VEGF-Trap: a VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America 2002 99 17 11393 11398 2-s2.0-0037143764 10.1073/pnas.172398299 (Pubitemid 34920936)
22. Brown D. M., Heier J. S., Ciulla T., Benz M., Abraham P., Yancopoulos G., Stahl N., Ingerman A., Vitti R., Berliner A. J., Yang K., Nguyen Q. D., Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011 118 6 1089 1097 2-s2.0-79957986348 10.1016/j.ophtha.2011.02.039
23. Lim J. Y., Lee S. Y., Kim J.-G., Lee J. Y., Chung H., Yoon Y. H., Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmologica 2012 90 1 61 67 2-s2.0-84856531921 10.1111/j.1755-3768.2009.01841.x
24. Heier J. S., Brown D. M., Chong V., Korobelnik J. F., Kaiser P. K., Nguyen Q. D., Kirchhof B., Ho A., Ogura Y., Yancopoulos G. D., Stahl N., Vitti R., Berliner A. J., Soo Y., Anderesi M., Groetzbach G., Sommerauer B., Sandbrink R., Simader C., Schmidt-Erfurth U., Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012 119 12 2537 2548
25. Barik S., Development of gene-specific double-stranded RNA drugs. Annals of Medicine 2004 36 7 540 551 2-s2.0-8544222783 10.1080/07853890410018817 (Pubitemid 39490963)
26. Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E., Mello C. C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998 391 6669 806 811 2-s2.0-0032545933 10.1038/35888 (Pubitemid 28099681)
27. Castanotto D., Rossi J. J., The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009 457 7228 426 433 2-s2.0-58749104364 10.1038/nature07758
28. Kaiser P. K., Symons R. C. A., Shah S. M., Quinlan E. J., Tabandeh H., Do D. V., Reisen G., Lockridge J. A., Short B., Guerciolini R., Nguyen Q. D., RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. American Journal of Ophthalmology 2010 150 1 33 39 2-s2.0-77953909544 10.1016/j.ajo.2010.02.006
29. Nguyen Q. D., Schachar R. A., Nduaka C. I., Sperling M., Klamerus K. J., Chi-Burris K., Yan E., Paggiarino D. A., Rosenblatt I., Aitchison R., Erlich S. S., Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 2012 119 9 1867 1873
30. Sabbadini R. A., Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. British Journal of Pharmacology 2011 162 6 1225 1238 2-s2.0-79951981180 10.1111/j.1476-5381. 2010.01118.x
31. Emerson M. V., Lauer A. K., Current and emerging therapies for the treatment of age-related macular degeneration. Clinical Ophthalmology 2008 2 2 377 388
32. Lpath, Inc., Efficacy and Safety Study of iSONEP with and without Lucentis/Avastin to Treat Age-Related Macular Degeneration (AMD) (Nexus) Bethesda, Md, USA National Library of Medicine (US). http://clinicaltrials.gov/ ct2/show/NCT01414153
33. Ohr Pharmaceutical Inc., Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects with Neovascular (Wet) Age-Related Macular Degeneration (AMD) Bethesda, Md, USA National Library of Medicine (US). http://clinicaltrials.gov/ ct2/show/NCT01678963
34. Xue Q., Hopkins B., Perruzzi C., Udayakumar D., Sherris D., Benjamin L. E., Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Research 2008 68 22 9551 9557 2-s2.0-56449087509 10.1158/0008-5472.CAN-08-2058
35. National Eye Institute (NEI), Palomid 529 in Patients with Neovascular Age-Related Macular Degeneration Bethesda, Md, USA National Library of Medicine (US)
36. Chen X., Li J., Li M., Zeng M., Li T., Xiao W., Li J., Wu Q., Ke X., Luo D., Tang S., Luo Y., KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF. Diabetes, Obesity and Metabolism 2013 15 3 224 233
37. Zhang M., Zhang J., Yan M., Luo D., Zhu W., Kaiser P. K., Yu D.-C., A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011 118 4 672 678 2-s2.0-79953328954 10.1016/j.ophtha.2010.08.008
38. MacLachlan T. K., Lukason M., Collins M., Munger R., Isenberger E., Rogers C., Malatos S., Dufresne E., Morris J., Calcedo R., Veres G., Scaria A., Andrews L., Wadsworth S., Preclinical safety evaluation of AAV2-sFLT01 a gene therapy for age-related macular degeneration. Molecular Therapy 2011 19 2 326 334 2-s2.0-79551622680 10.1038/mt.2010.258
39. Lukason M., Dufresne E., Rubin H., Pechan P., Li Q., Kim I., Kiss S., Flaxel C., Collins M., Miller J., Hauswirth W., MacLachlan T., Wadsworth S., Scaria A., Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Molecular Therapy 2011 19 2 260 265 2-s2.0-79551652669 10.1038/mt.2010.230
40. Eric H. Souied, e.a., ARVO abstract [3541/A339], 2011
41. Molecular Partners AG, A Phase I/II, Open-Label, Non-Controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients with Wet Age Related Macular Degeneration (AMD) 2010 Bethesda, Md, USA National Library of Medicine (US). http://clinicaltrials.gov/ct2/show/NCT01086761
42. Rahimi N., VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Frontiers in Bioscience 2006 11 1 818 829 2-s2.0-33144459287 (Pubitemid 43262905)
43. Kaiser P. K., Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. American Journal of Ophthalmology 2006 142 4 660 e1 2-s2.0-33748979577 10.1016/j.ajo.2006.05.061 (Pubitemid 44442083)
44. Novartis, N.C.I., Safety and Efficacy of Oral PTK787 in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (ADVANCE) Bethesda, Md, USA National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00138632
45. Sonpavde G., Hutson T. E., Sternberg C. N., Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opinion on Investigational Drugs 2008 17 2 253 261 2-s2.0-39049095199 10.1517/13543784.17.2.253 (Pubitemid 351578205)
46. GlaxoSmithKline, A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers Bethesda, Md, USA National Library of Medicine (US). http://clinicaltrials.gov/show/NCT01072214
47. Dugel P. U., Bebchuk J. D., Nau J., Reichel E., Singer M., Barak A., Binder S., Jackson T. L., Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013 120 2 317 327
48. Moshfeghi D. M., Kaiser P. K., Gertner M., Stereotactic low-voltage X-ray irradiation for age-related macular degeneration. British Journal of Ophthalmology 2011 95 2 185 188 2-s2.0-79151481849 10.1136/bjo.2009.163907
49. Parsons J. T., Bova F. J., Fitzgerald C. R., Mendenhall W. M., Million R. R., Radiation retinopathy after external-beam irradiation: analysis of time- dose factors. International Journal of Radiation Oncology Biology Physics 1994 30 4 765 773 2-s2.0-0028052061 (Pubitemid 24355923)
50. Oraya Therapeutics, Inc., A Double-Masked, Sham Controlled, Dose-Ranging Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Patients with Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD). http://clinicaltrials.gov/show/ NCT01016873
51. Cross W. G., Hokkanen J., Järvinen H., Mourtada F., Sipilä P., Soares C. G., Vynckier S., Calculation of beta-ray dose distributions from ophthalmic applicators and comparison with measurements in a model eye. Medical Physics 2001 28 7 1385 1396 2-s2.0-0034919040 10.1118/1.1376442 (Pubitemid 32667277)
52. van Ginderdeuren R., Van Limbergen E., Spileers W., 18 Years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma. British Journal of Ophthalmology 2005 89 10 1306 1310 2-s2.0-27744471059 10.1136/bjo.2005.068460 (Pubitemid 41638871)
53. Ávila M. P., Farah M. E., Santos A., Duprat J. P., Woodward B. W., Nau J., Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. British Journal of Ophthalmology 2009 93 3 305 309 2-s2.0-61749100479 10.1136/bjo.2008.145912
54. Jackson T. L., Kirkpatrick L., Tang G., Prasad S., Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration. Eye 2012 26 4 557 563 2-s2.0-84859758565 10.1038/eye.2011.351
55. Dugel P. U., Petrarca R., Bennett M., Barak A., Weinberger D., Nau J., Jackson T. L., Macular epiretinal brachytherapy in treated age-related macular degeneration. MERITAGE study: twelve-month safety and efficacy results. Ophthalmology 2012 119 7 1425 1431 2-s2.0-84858979940 10.1016/j.ophtha.2012.01. 014
56. Gaengel K., Genové G., Armulik A., Betsholtz C., Endothelial-mural cell signaling in vascular development and angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 5 630 638 2-s2.0-65249173169 10.1161/ATVBAHA.107.161521
57. Ophthotech Corporation, A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects with Neovascular Age-Related Macular Degeneration 2012
58. Ophthotech Corporation, A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration 2012
59. Kaiser P. K., Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline. Ophthalmology 2013 120 supplement 5 S11 S15 10.1016/j.ophtha.2013.01.061
60. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655 (Pubitemid 44511558)
61. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
62. Duh E. J., Yang H. S., Suzuma I., Miyagi M., Youngman E., Mori K., Katai M., Yan L., Suzuma K., West K., Davarya S., Tong P., Gehlbach P., Pearlman J., Crabb J. W., Aiello L. P., Campochiaro P. A., Zack D. J., Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Investigative Ophthalmology and Visual Science 2002 43 3 821 829 2-s2.0-0036184047 (Pubitemid 34184503)
63. Mori K., Gehlbach P., Ando A., McVey D., Wei L., Campochiaro P. A., Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Investigative Ophthalmology and Visual Science 2002 43 7 2428 2434 2-s2.0-0036297886 (Pubitemid 34700678)
64. 2-s2.0-33846973642 10.1097/IAE.0b013e3180323de7